House Democrats say a CBO analysis shows the bill will "rein in the soaring cost of prescription drugs and level the playing field for American patients."
The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.
The investor urges Cigna shareholders to reject the acquisition of Express Scripts, calling it potentially “one of the worst blunders in corporate history."
